Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Up 625.2% in February

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a significant increase in short interest in February. As of February 27th, there was short interest totaling 65,445 shares, an increase of 625.2% from the February 12th total of 9,025 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 79,373 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 79,373 shares, the short-interest ratio is currently 0.8 days. Currently, 0.0% of the company’s shares are short sold.

Fresenius SE & Co. Stock Up 0.4%

Shares of FSNUY stock traded up $0.05 during trading hours on Tuesday, hitting $14.02. 112,026 shares of the company were exchanged, compared to its average volume of 67,351. Fresenius SE & Co. has a 52 week low of $9.78 and a 52 week high of $33.93. The company has a current ratio of 1.26, a quick ratio of 0.99 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average of $14.56 and a two-hundred day moving average of $14.45. The company has a market capitalization of $31.59 billion, a PE ratio of 22.25 and a beta of 0.75.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.28 EPS for the quarter. The business had revenue of $6.94 billion for the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.38%. Analysts anticipate that Fresenius SE & Co. will post 0.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on FSNUY. Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, December 15th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.